drugset
drugset / Trial / NCT00049582

Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT00049582 ↗

Phase 1 Terminated 36 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of decitabine in treating patients with myelodysplastic syndromes or acute myeloid leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Timeline

Start
2002-09
Primary completion
2010-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule — Intravenous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute promyelocytic leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative myelodysplastic syndrome myeloproliferative neoplasm, unclassifiable